Aptitude Medical Systems, a company focused on infectious disease diagnostics, has announced a new $9 million partnership with the Biomedical Advanced Research and Development Authority. The project centers around developing the Metrix Filovirus Panel, a rapid molecular test that can detect and differentiate between Ebolavirus and Marburgvirus species.
According to a news release, this is Aptitude’s second collaboration with BARDA, following an earlier partnership that advanced the Metrix platform and secured up to $61.9 million in funding.
The new funding will support the panel’s development and regulatory approval.
In a statement, Aptitude’s JP Wang added, “This collaboration enables the use of blood samples on the Metrix platform, for the first time, significantly expanding the power of the platform to a wide range of applications.”
